Semaglutide Production via Semapeptide Recombinant Process
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for the industrial production of semaglutide lack an efficient and improved recombinant process, despite existing processes via semi-recombinant and synthetic methods.
Innovation Solution
A recombinant process involving the culturing of host cells with specific nucleotide sequences for expression, incorporating insoluble and affinity tags, followed by fermentation and purification steps to produce semapeptide, which is then converted into semaglutide, enhancing accumulation and isolation efficiency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If semi-recombinant or synthetic methods are used for semaglutide preparation, then production can be achieved, but production efficiency and yield are insufficient for industrial scale
Solution Approach 1:
The patent introduces semapeptide as an intermediary substance that serves as a precursor to semaglutide. By producing semapeptide through recombinant DNA technology in host cells and then converting it to semaglutide through enzymatic reactions, the process achieves higher production efficiency and yield compared to direct synthetic methods. The intermediary semapeptide enables a two-step pathway that improves overall productivity.
Solution Approach 2:
The patent employs parameter changes by utilizing different host cells (such as E. coli, yeast, or mammalian cells) with optimized genetic sequences to maximize semapeptide production. By adjusting cultivation conditions, temperature, pH, and nutrient composition, the process achieves optimal yield and production efficiency for industrial scale manufacturing.
2Quantity of substance
If recombinant process with fusion tags is used, then accumulation and purification of semapeptide is improved, but process complexity increases
Solution Approach 1:
The patent applies preliminary action by incorporating fusion tags (such as His-tag, GST-tag, or MBP-tag) onto the N- or C-terminus of semapeptide during the recombinant expression stage. These tags are added in advance to facilitate subsequent purification steps through affinity chromatography, enabling easier separation and accumulation of semapeptide without requiring complex purification procedures later.
Solution Approach 2:
The fusion tags act as intermediary elements that simplify the purification process. By using tags like His-tag that can be selectively bound by affinity chromatography resins, the patent enables straightforward separation of semapeptide from host cell proteins and other contaminants, reducing overall process complexity despite the additional tagging step.
3Productivity
If fermentation process is optimized for semapeptide accumulation, then production efficiency improves, but purification difficulty increases
Solution Approach 1:
The patent applies preliminary action by incorporating purification elements (fusion tags and affinity chromatography capabilities) during the fermentation and expression stage. This preliminary preparation ensures that semapeptide can be easily purified in subsequent steps through affinity chromatography, maintaining high accumulation efficiency while actually simplifying the purification process rather than increasing difficulty.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This process improves the production efficiency of semaglutide by optimizing the accumulation and purification of semapeptide during fermentation, leading to higher yields and purity.
Implementation Method 1
culturing a host cell comprising a nucleotide sequence encoding of Formula (II) under suitable conditions for expression
Implementation Method 2
increase in accumulation of resulting semapeptide by fermentation process
Data Source
AI summary
The present application relates to a process for the preparation of semaglutide. The present application also relates to a recombinant process for the preparation of semapeptide. The present invention is related to a process for producing semapeptide, the process comprising the steps of, a) culturing a host cell comprising a nucleotide sequence encoding of Formula (II) under suitable conditions for expression, wherein, insoluble tag is a nucleotide sequence of Alanine-Valine; b) recovering semapeptide, wherein semapeptide amino acid sequence is Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly.